Pacira BioSciences (PCRX) – Trader Talk
-
Needham & Company Reiterates Buy Rating, $84 PT on Pacira Pharmaceuticals (PCRX), Continue to Expect Significant Sales Growth Rebound
-
Pacira Pharma (PCRX): HRTX CRL a 'Clear Positive' - RBC
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to PCRX Stock Lookup